nach oben

Journal of Neural Transmission

Erschienen in:

29.10.2017 | Psychiatry and Preclinical Psychiatric Studies - Short communication

The role of depression pharmacogenetic decision support tools in shared decision making

verfasst von: Katarina Arandjelovic, Harris A. Eyre, Eric Lenze, Ajeet B. Singh, Michael Berk, Chad Bousman

Erschienen in: Journal of Neural Transmission | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Patients discontinue antidepressant medications due to lack of knowledge, unrealistic expectations, and/or unacceptable side effects. Shared decision making (SDM) invites patients to play an active role in their treatment and may indirectly improve outcomes through enhanced engagement in care, adherence to treatment, and positive expectancy of medication outcomes. We believe decisional aids, such as pharmacogenetic decision support tools (PDSTs), facilitate SDM in the clinical setting. PDSTs may likewise predict drug tolerance and efficacy, and therefore adherence and effectiveness on an individual-patient level. There are several important ethical considerations to be navigated when integrating PDSTs into clinical practice. The field requires greater empirical research to demonstrate clinical utility, and the mechanisms thereof, as well as exploration of the ethical use of these technologies.

Akincigil A et al (2007) Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care 45(4):363–369PubMedPubMedCentralCrossRef

Alguera-Lara V et al (2017) Shared decision making in mental health: the importance for current clinical practice. Australas Psychiatry. doi:10.1177/1039856217734711

Berk L et al (2010) Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol 25(1):1–16PubMedCrossRef

Bousman CA, Hopwood M (2016) Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3(6):585–590PubMedCrossRef

Brennan FX et al (2015) A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord 17(2). doi:10.4088/PCC.14m01717.

Charles C, Gafni A, Whelan T (1999) Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 49(5):651–661PubMedCrossRef

Coulter A et al (2015) Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev 3:CD010523

Data-Franco J, Berk M (2013) The nocebo effect: a clinicians guide. Aust N Z J Psychiatry 47(7):617–623PubMedCrossRef

Demyttenaere K et al (2001) Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62(Suppl 22):30–33PubMed

Dodd S et al (2015) Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry 76(6):702–711PubMedCrossRef

Dunlop BW et al (2012) Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res 46(3):375–381PubMedCrossRef

Durand MA et al (2014) Do interventions designed to support shared decision-making reduce health inequalities? A systematic review and meta-analysis. PLoS One 9(4):e94670PubMedPubMedCentralCrossRef

Hall-Flavin DK et al (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2:e172PubMedPubMedCentralCrossRef

Hall-Flavin DK et al (2013) Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genom 23(10):535–548CrossRef

Hawley ST, Morris AM (2017) Cultural challenges to engaging patients in shared decision making. Patient Educ Couns 100(1):18–24PubMedCrossRef

Hibbard JH (2017) Patient activation and the use of information to support informed health decisions. Patient Educ Couns 100(1):5–7PubMedCrossRef

IPDAS (2013) International Patient Decision Aid Standards (IPDAS) Collaboration. http://ipdas.ohri.ca/. Accessed 18 Oct 2016

LeBlanc A et al (2015) Shared decision making for antidepressants in primary care: a cluster randomized trial. JAMA Intern Med 175(11):1761–1770PubMedPubMedCentralCrossRef

Lemire M et al (2008) Determinants of Internet use as a preferred source of information on personal health. Int J Med Inform 77(11):723–734PubMedCrossRef

Loh A et al (2007) The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Couns 67(3):324–332PubMedCrossRef

Mayo (2011) Depression Medication Choice. http://shareddecisions.mayoclinic.org/decision-aid-information/decision-aids-for-chronic-disease/depression-medication-choice/. Accessed 18 Oct 2016

Mcmanus P et al (2004a) Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 38(6):450–454PubMedCrossRef

Mcmanus P et al (2004b) Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 38(6):450–454PubMedCrossRef

Milton AC, Mullan BA (2014) Communication of a mental health diagnosis: a systematic synthesis and narrative review. J Ment Health 23(5):261–270PubMedCrossRef

Mulsant BH et al (2014) A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med 30(3):517–534PubMedPubMedCentralCrossRef

ORYGEN (2016) Clinical practice point: shared decision making for youth mental health. Orygen, Melbourne. https://www.orygen.org.au/Skills-Knowledge/Resources-Training/Resources/Free/Clinical-Practice/Shared-decision-making

Perestelo-Perez L et al (2017) Effectiveness of a decision aid for patients with depression: a randomized controlled trial. Health Expect 20:1096–1105PubMedPubMedCentralCrossRef

Perez V et al (2017) Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1):250PubMedPubMedCentralCrossRef

Pérez V et al (2017) Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17:250PubMedPubMedCentralCrossRef

Peterson K et al (2016) Evidence brief: the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Department of Veterans Affairs, Washington, DC

Peterson K et al (2017) Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 234(11):1649–1661PubMedCrossRef

Raue PJ et al (2010) Shared decision-making in the primary care treatment of late-life major depression: a needed new intervention? Int J Geriatr Psychiatry 25(11):1101–1111PubMedPubMedCentralCrossRef

Rief W, Glombiewski J (2016) Erwartungsfokussierte Psychotherapeutische Interventionen (EFPI). Verhaltenstherapie 26(1):47–54CrossRef

Rief W, Glombiewski A (2017) The role of expectations in mental disorders and their treatment. World Psychiatry 16(2):210–211PubMedPubMedCentralCrossRef

Robinson WD et al (2005) Depression treatment in primary care. J Am Board Fam Pract 18(2):79–86PubMedCrossRef

Rosenblat JD, Lee Y, McIntyre RS (2017) Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 78:720–729PubMedCrossRef

Rush AJ et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163(11):1905–1917PubMedCrossRef

Schattner A, Bronstein A, Jellin N (2006) Information and shared decision-making are top patients’ priorities. BMC Health Serv Res 6:21PubMedPubMedCentralCrossRef

Schouten BC, Meeuwesen L (2006) Cultural differences in medical communication: a review of the literature. Patient Educ Couns 64(1–3):21–34PubMedCrossRef

Sheehan DV et al (2008) Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22(11):963–973PubMedCrossRef

Singh AB (2015) Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 13(2):150–156PubMedPubMedCentralCrossRef

Sirey J, Bruce M, Kales H (2010) improving antidepressant adherence and depression outcomes in primary care: the treatment initiation and participation program. Am J Geriatr Psychiatry 18(6):554–562PubMedPubMedCentralCrossRef

Sirey JA et al (2013) Medication beliefs and self-reported adherence among community-dwelling older adults. Clin Ther 35(2):153–160PubMedPubMedCentralCrossRef

Sirey JA et al (2017) Adherence to depression treatment in primary care: a randomized clinical trial. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.3047

Slade M (2017) Implementing shared decision making in routine mental health care. World Psychiatry 16(2):146–153PubMedPubMedCentralCrossRef

Solberg LI et al (2014) How much shared decision making occurs in usual primary care of depression? J Am Board Fam Med 27(2):199–208PubMedCrossRef

Stacey D et al (2014) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1:CD001431

Stacey D et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 4:CD001431PubMed

Tecuta L et al (2015) Demoralization: a systematic review on its clinical characterization. Psychol Med 45(4):673–691PubMedCrossRef

Thase ME et al (2010) Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 25(4):189–198PubMedCrossRef

Thompson C, Steven PH, Catriona H (2015) Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res 226(1):68–72PubMedCrossRef

van Grieken RA et al (2014) Patients perspectives on how treatment can impede their recovery from depression. J Affect Disord 167:153–159PubMedCrossRef

Walden LM et al (2015) Physicians’ opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res 229(3):913–918PubMedCrossRef

Winner JG et al (2013) A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 16(89):219–227PubMed

Titel: The role of depression pharmacogenetic decision support tools in shared decision making
verfasst von: Katarina Arandjelovic
Harris A. Eyre
Eric Lenze
Ajeet B. Singh
Michael Berk
Chad Bousman
Publikationsdatum: 29.10.2017
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 1/2019
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-017-1806-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of depression pharmacogenetic decision support tools in shared decision making

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Towards pharmacogenetic-based treatment in psychiatry

Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders

Blood-based biomarkers predicting response to antidepressants

Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain

An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes

The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie